Via Nova Therapeutics

About:

Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections.

Website: https://vianovatx.com/

Top Investors: Aditum Bio

Description:

Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses, and rhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The company targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well.

Total Funding Amount:

$25M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Oakland, California, United States

Founded Date:

2020-01-01

Founders:

Don Ganem, Kelly Wong

Number of Employees:

1-10

Last Funding Date:

2021-09-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai